A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market worth billions a year.

Brazil will pilot Ozempic-style weight-loss drugs in its public health system, a demand signal for Novo Nordisk and Eli Lilly once prices fall.

A South African court has ordered pharmacy group iDexis to halt sales of semaglutide-based medicines in a legal victory for Novo Nordisk, maker of Ozempic and Wegovy